Clearmind Medicine submits US patent application for combination with SciSparc

Clearmind Medicine (CMND) has submitted an additional patent application with the USPTO, as part of its ongoing collaborations with SciSparc (SPRC) and with Prof. Joseph Tam from the Hebrew University’s technology transfer company, Yissum. The patent application refers to the novel proprietary composition of Clearmind’s MEAI compound with Palmitoylethanolamide, the active ingredient of SciSparc’s proprietary CannAmide, for treating metabolic syndrome and obesity. Among adults aged 20 and over, the prevalence of obesity was 41.9%. The global obesity treatment market size was valued at $15B in 2022 and is expected to register a rapid revenue CAGR of 10.0% during the forecast period of 2023 to 2032. As part of the collaboration with SciSparc, twelve other patent applications have been filed by Clearmind with the USPTO for various proprietary compositions, including the composition of SciSparc’s PEA with Clearmind’s MEAI compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.